Archive: 28/10/2014
Drug for rare paroxysmal nocturnal hemoglobinuria receives FDA orphan status
A Penn Medicine-developed drug has received orphan status from the Food and Drug Administration (FDA) this month for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a rare, life-threatening disease that causes ...
Oct 28, 2014